Tesla: Shares Rally as Robotaxi Testing Expands to Arizona

In our view, Tesla’s robotaxi business is nearly priced for perfection.

The exterior of a Tesla store.
Jeremy Moeller via Getty
Securities in This Article
Tesla Inc
(TSLA)

Key Morningstar Metrics for Tesla

Bloomberg reported that Tesla TSLA received approval to begin testing its robotaxi, an autonomous driving ride-hailing service, in the US state of Arizona. Tesla shares were up 4% at the time of writing on Sept. 22.

Why it matters: Arizona is the fourth state where Tesla will be testing its robotaxi service, following current testing in Texas, California, and Nevada. The expansion to a new market signals that the current testing is going well enough to expand.

  • Tesla’s rapid testing expansion would let it quickly offer robotaxis in multiple cities when the software develops to the point where Tesla can move from testing to a full product.
  • A market entrance in multiple cities supports our view that robotaxis will quickly expand and gain market share. We think Tesla will eventually capture 30% of the US and Canada ride-hailing market by 2035.

The bottom line: We maintain our $250 fair value estimate for narrow-moat Tesla. We view shares as significantly overvalued, with the stock trading more than 75% above our fair value estimate. In our view, Tesla’s robotaxi business is nearly priced for perfection.

  • We continue to forecast Tesla’s full robotaxi service to launch in 2028, two years behind management’s guidance for a 2026 launch. We define a full launch as a robotaxi with no Tesla employees on board and no geofencing. Currently, robotaxis in testing have both.
  • Tesla’s autonomous driving system offers the ability to scale and enter new markets. This is because its camera-only approach can take its ability to drive safely in one place and recognize how to drive safely in a different location. This should allow Tesla to grow faster than peers.

Editor’s Note: This analysis was originally published as a stock note by Morningstar Equity Research.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

Sponsor Center